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Abstract 
The popularity and prevalence of cosmeceutical products is growing at an 
unprecedented  rate  both  domestically  and  abroad.  In  the  United  States, 
cosmeceuticals are typically regulated as cosmetics even though these products 
often offer drug-like benefits. As the efficacy claims, technology and science used 
in these products continues to advance, the application of the pure cosmetics 
regulatory scheme under the FDCA grows increasingly problematic. This paper 
aims to discuss why the existing legal system is ill equipped to properly monitor 
the modern cosmeceutical industry and it attempts to suggest possible ways to 
improve the oversight of these products. Part I sets the stage by examining the 
current  cosmeceutical  industry.  Part  II  reviews  the  historical  and  current 
regulatory framework of both cosmetics and drugs. Part III looks at two modern 
day cosmeceuticals, eyelash growth products and anti-age creams with stem-cell 
technology, to further analyze why existing regulations are insufficient to protect 
consumers.  Part  IV  proposes  several  possible  modifications  to  the  current 
regulation  of  cosmeceuticals,  ultimately  recommending  the  creation  of  a  new 
cosmeceuticals category under the FDCA. Part V concludes. 
 
 
 
 
   2 
Part I: Introduction 
Professor  Albert  Klingman  of  the  University  of  Pennsylvania  first 
popularized the term “cosmeceuticals” in 1979.
1 The term was initially coined to 
describe a class of face creams that claimed to do more than merely “decorate or 
camouflage,” given the inclusion of active ingredients, which were intended to 
provide  additional  health  benefits.
2  In  the  past  few  decades,  this  category  of 
products  has  greatly  expanded  to  reflect  a  growing  array  of  personal  care 
products that remain regulated as cosmetics but are marketed as offering drug-
like advantages. Ranging from creams and serums that are “packed with extra 
ingredients, like Alpha Hydroxy Acids, Ester-C, and copper peptides said to have 
therapeutic benefits,”
3 to applications that promise to moisturize and thicken hair, 
the  term  cosmeceutical  has  gained  significant  momentum  as  it  appropriately 
describes the current realities of the modern cosmetics industry.  
Today, the cosmeceutical market represents one of the fastest growing 
segments  within  personal  care  products.  According  to  one  market  research 
company, cosmeceutical skincare products alone accounted for more than $6.4 
billion in domestic sales in 2004, with an estimated increase to over $16 billion by 
2010.
4  Another consulting firm noted, “the global market for cosmeceuticals is 
                                                        
1 Albert Klingman, Cosmeceuticals: Do We Need a New Category? in COSMECEUTICALS 
1 (Peter Elsner & Howard I. Maibach, eds., 2000). 
2 See Klingman, supra note 1, at 4. 
3 Erika Kawalek, Artfully Made-Up, 2005-DEC Legal Aff. 54. (2005) 
4 Kawalek, supra note 2.   3 
growing  nearly  twice  as  fast  as  the  overall  cosmetics  and  toiletries  market.”
5 
Fueled by an aging generation of baby-boomers and a growing obsession with 
youthfulness  and  wellness,
6  these  products,  which  are  often  more  readily 
available than prescription drugs, present an extremely attractive option to a wide 
consumer  base.  Furthermore,  given  the  recent  advancements  in  scientific 
technologies such as the development of nanotechnology, DNA technology and 
stem cell research, the potential for new products is overwhelming. Hence it is no 
surprise that established cosmetics companies, new biotech manufacturers and 
even some traditional pharmaceutical companies have flushed the market with 
the production of numerous cosmeceuticals in an attempt to take advantage of 
this extremely lucrative, high-margin business.  
Unfortunately, the law in this area has been slow to react to the changes 
and modernization of cosmetics. The Food, Drug and Cosmetic Act (FDCA), the 
statute primarily responsible for the regulation of cosmetics, does not currently 
recognize cosmeceuticals as a valid legal category. Instead, the FDCA retains its 
original framework, classifying an article as either a drug or a cosmetic (and very 
occasionally, as both) based on the productʼs intended use.
7 More specifically, a 
product will be deemed a cosmetic if it is intended to be:  
                                                        
5 Scientia Advisors Press Release, available at http://www.scientiaadv.com/pr_2009-11-
04.php (last visited March 30, 2011)  
6 Victoria Farren, Removing the Wrinkle in Cosmetics and Drug Regulation: A Notice 
Rating System and Education Proposal for Anti-Aging Cosmeceuticals, 16 Elder L.J. 
375, 376 (2009). 
7 Food and Drug Administration Website, 
http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/ucm074201.h
tm (last visited March 30, 2011)   4 
“(1)  rubbed,  poured,  sprinkled,  or  sprayed  on,  or  introduced  into,  or 
otherwise applied to the human body or any part thereof for cleansing, 
beautifying, promoting attractiveness, or altering the appearance and (2) 
articles intended for use as a component of any such articles; except that 
such term shall not include soap.”
8  
 
By contrast, a product is regulated as a drug if it is:  
“(b)  intended  for  use  in  the  diagnosis,  cure,  mitigation,  treatment,  or 
prevention of disease in man or other animals; and (c) articles (other than 
food) intended to affect the structure or any function of the body of man or 
other animals."
9 
 
Since cosmeceutical products tend to be topical and carefully positioned as only 
intending  to  affect  oneʼs  temporary  appearance,  manufacturers  are  generally 
able to evade the much stricter regulatory approval process imposed on drugs. 
However it seems that from a functional perspective, these products are better 
described  as  actually  falling  somewhere  along  the  cosmetic-drug  spectrum.  
Thus,  simply  permitting  cosmeceuticals to  continue  to  be  regulated under  the 
minimal  cosmetics  standard  is  highly  problematic.  Not  only  is  the  threat  of  a 
greater number of inadequately tested products reaching the market amplified, 
but the number of manufacturers that are able to benefit from making deceptively 
unsubstantiated claims at the expense of the consumersʼ pocketbooks is also 
immense. In light of this new generation of cosmetics, the FDA should strongly 
consider amending its current approach to the regulation (or rather lack thereof) 
of cosmeceuticals. More oversight is needed to appropriately monitor the safety 
of these products that use newly discovered ingredients and technologies, which 
may  present  unknown  risks  and  effects.  Additionally,  the  FDA  must  consider 
                                                        
8 21 U.S.C. sec. 321(i) (emphasis added).  
9 21 U.S.C. sec. 321(g)(1) (emphasis added).   5 
ways  in  which  it  can  better  protect  consumers  from  the  increasingly  bold 
statements about cosmeceutical efficacy in situations where there is insufficient 
data supporting such claims.    
This paper aims to discuss why the existing legal system is ill equipped to 
properly  monitor  the  growing  cosmeceutical  industry  and  to  suggest  possible 
ways to improve the oversight of these products. Part II reviews the historical and 
current  regulatory  framework  of  cosmetics  and  drugs.  Part  III  discusses  the 
insufficiency  of  the  existing  approach  from  both  a  safety  and  economics 
perspective through an analysis of several modern-day cosmeceutical examples, 
including the recently trendy eyelash enhancer products and the newest fad in 
anti-aging  creams:  the  use  of  stem-cell  technology.  Part  IV  proposes  several 
possible  modifications  to  the  current  regulation  of  cosmeceuticals,  ultimately 
recommending the creation of a new cosmeceuticals category under the FDCA. 
Part V concludes. 
 
Part II: Historical and Current Regulation of the Cosmetics Industry 
  The Food, Drug and Cosmetic Act (FDCA) was enacted in 1938.
10 The 
passage of the FDCA represented the first time the FDA was given power to 
regulate  the  cosmetics  industry.
11  Several  tragedies  involving  dangerous 
cosmetics such as the depilatory Koremlu Cream and the infamous Lash Lure 
                                                        
10 Peter Barton Hutt, Legal distinction in the United States Between a Cosmetic and a 
Drug, in COSMECEUTICALS 223, 225 ((Peter Elsner & Howard I. Maibach, eds., 2000). 
11  Laura A. Heymann, The Cosmetic/Drug Dilemma: FDA Regulation of Alpha-Hydroxy 
Acids, 52 Food & Drug L.J. 357, 361 (1997)   6 
product,  both  of  which  contained  highly  poisonous  chemicals,  provided  the 
necessary catalyst for the change.
12 While bringing cosmetics under the control 
of the FDA represented an important and necessary step in promoting public 
safety, the actual contours surrounding the regulation of cosmetics were (and 
are)  quite  limited.
13  Under  the  FDCA,  cosmetics  are “ prohibited  from  being 
adulterated or misbranded, but, with the exception of color additives, they are not 
subject to premarket approval, safety or efficacy testing, or good manufacturing 
practices.”
14 Astonishingly, the FDCA remains largely unchanged from its original 
1938  form  as  to  the  cosmetic  portions  of  the  Act.
15  Despite  the  significant 
changes  that  have  occurred  in  the  science  involved  in  producing  cosmetics, 
which was even recognized by the Commissioner of Food and Drugs back in 
1988, the governing law has nonetheless stayed relatively constant.
16 Cosmetics 
continue to represent the least restrictive category under FDA supervision, and to 
this day, cosmetics represent the only “major FDA-regulated product group that 
does not have its own center within the FDA.”
17 
18 
                                                        
12 Amity Hartman, FDAʼs Minimal Regulation of Cosmetics and the Daring Claims of 
Cosmetic Companies that Cause Consumers Economic Harm, 36 W. St. U. L. Rev. 53, 
55 (2008)  
13 Id. 
14 Jacqueline A. Greff, “Regulation of Cosmetics that are Also Drugs,” 51 Food & Drug 
L.J. 243 (1996) 
15 Peter Barton Hutt, supra note 10, at 237.  
16 Heymann, supra note 11, at 370. 
17 Greff, supra note 14, at 248.  
18 Cosmetics continue to be primarily regulated by the Center for Food Safety and 
Applied Nutrition (CFSAN), though the Center for Drug Evaluation and Research (CDER) 
has concurrent jurisdiction over products that purport to be cosmetic but meets the 
definition of a drug. See CDER-CFSAN Cosmetic Agreement available at 
http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/ComplianceE
nforcement/ucm2005170.htm (last visited April 1, 2011).   7 
Specifically, the FDCA operates by imposing intent-centered definitions, 
which are used to distinguish a cosmetic from a drug.
19 Thus most products will 
fall into either the drug category or the cosmetics category, although since the 
definitions are not mutually exclusive, some products may need to satisfy both 
standards.
20 Because there is a sharp contrast in the level of regulation and FDA 
involvement depending on whether an article is a drug or cosmetic, there is a 
strong incentive for cosmeceutical manufacturers to avoid the much harsher drug 
framework  by  attempting  to  place  their  products  within  the  confines  of  the 
cosmetics definition. As noted above, the main factor determining a productʼs 
categorization  as  either  a  drug  or  cosmetic  is  the  productʼs  intended  use. 
21 
Namely, if an article is intended to affect the structure or function of the body 
based on its labeling and advertising, the product will be regulated as a drug; by 
contrast, if a product only makes vague claims about how it will impact oneʼs 
appearance, it will likely be classified as a cosmetic.
22 Thus, “whether a product 
actually has an effect on a structure or function of the body [is] irrelevant: If the 
manufacturer claims it does, it is considered a drug; if it does not, it is considered 
a cosmetic. A dangerous chemical for which only cosmetic claims were made 
might  avoid  premarket  regulation,  whereas  a  claim  that  a  product  consisting 
                                                        
19 See generally, 21 U.S.C. sec. 321. 
20 Klingman, supra note 1, at 3. 
21 Greff, supra note 14, at 253. 
22  Heymann, supra note 11, at 370.   8 
wholly  of  water  would  ʻplump  up  skin  cellsʼ  would  cause  the  product  to  be 
regulated as a drug.”
23   
Drug regulation under the FDCA is extremely time-consuming and subject 
to extensive oversight. Cosmetics on the other hand are only required to adhere 
to  minimal  FDA-established  requirements.  More  specifically,  in  the  areas  of 
“approval  requirements,  good  manufacturing  practices,  registration  and 
labeling,”
24 drugs are subject to much stricter regulatory hurdles. For instance, 
drugs must receive premarket approval by the FDA before they are permitted to 
reach the market.
25 During this premarket review process, the product is vetted 
and scrutinized by the FDA as to the safety and efficacy of the product.
26 Only 
after the agency has tested and approved the drug will it be available to end-
consumers.  
Additionally,  drug  manufacturers  are  required  to  register  their 
manufacturing establishments and all drug products with the FDA (specifically 
with  the  Secretary  of  the  Department  of  Health  and  Human  Services).
27  By 
mandating registration, the FDA can properly track and monitor drugs available 
on the market. Drug producers must also conform to current good manufacturing 
practice (GMP) requirements, which are set forth in FDA regulations,
28 and these 
                                                        
23 Id. at 366. 
24 Farren, supra note 6, at 383. 
25 Id.  
26 Heymann, supra note 11, at 364. 
27 Stephen H. McNamara, Regulation of Cosmetics in the United States – An Overview, 
in THE COSMETICS INDUSTRY: SCIENTIFIC AND REGULATORY FOUNDATIONS, 4, 11 (Norman 
F. Estrin, ed., 1984).  
28 Id.   9 
companies are required to report product-related injuries to the agency on an on-
going basis.
29 Finally, drugs are subject to onerous labeling requirements given 
the  FDA  requires  any  drug  product  to  identify  active  ingredients  on  both  its 
packaging and the immediate container of the drug.
30 
In contrast to these rigorous requirements that have been established for 
drugs,  cosmetics  are  subject  to  a  much  looser  regulatory  framework.  Most 
significantly, cosmetics do not need to pass any premarket clearance before they 
are  available  on  the  market,  with  a  limited  exception  for  color  additives  and 
certain prohibited ingredients.
31  Because there is no FDA-enforced premarket 
approval system, the potential dangers of a cosmetic are often not discovered 
until  after  the  product  has  already  been  on  the  market  and  caused  harm  to 
consumers.
32    Moreover,  the  lack  of  premarket  review  implies  that  cosmetic 
manufacturers are not even required to prove their products are generally safe or 
effective in what they claim to do before they are sold to naïve consumers.
33  
Instead,  protection  of  the  public  is  achieved  primarily  through  the 
adulteration and misbranding provisions of the FDCA, and “the requirement that 
a cosmetic ingredient or product that has not been adequately substantiated for 
safety prior to marketing be conspicuously labeled ʻWarning -- The safety of this 
product  has  not  been  determined.ʼ”
34  Cosmetics  are  also  subject  to  The  Fair 
                                                        
29 Greff, supra note 14, at 247. 
30 Id. (quoting 21 U.S.C. 321(g)(1)) 
31 Farren, supra note 6, at 383. 
32 Heymann, supra note 11, at 363. 
33 Id.  
34 Greff, supra note 14, at 248.   10 
Packaging  and  Labeling  Act  of  1973,  and  thus  cosmetic  manufacturers  are 
required to include ingredient statement labels on the products that are sold to 
consumers.
35 In particular, the FDA regulations provide that cosmetic products 
must include the following information: “the cosmetic name, quantity, name and 
place  of  business  of  the  manufacturer  and  ingredients  listed  in  order  of 
predominance.”
36 However, unlike drug labels, pure cosmetics are not required to 
separately list any active ingredients used in the product (unless of course, the 
product is also classified as an over-the-counter drug).
37  
Additionally, unlike their drug counterpart, cosmetics are not subject to any 
FDA established GMP requirements nor are cosmetic manufacturers required to 
register  their  establishment  or  their  product  formulations  with  the  agency.
38 
Although  cosmetic  companies  may  voluntarily  register  themselves  with  the 
Voluntary  Cosmetic  Registration  Program,  the  FDA's  Office  of  Cosmetics  and 
Colors state that only about 35% to 40% of cosmetics manufacturers participate 
in the program.
39 Cosmetic companies also do not have the duty to report any 
injuries or complaints it receives from consumers regarding its products, though 
again,  the  company  may  report  such  incidents  to  the  Voluntary  Cosmetic 
Reporting Program.
40 As this comparison makes obvious, the greatest difference 
                                                        
35 Roseann B. Termini and Leah Tressler, American Beauty: An Analytical View of the 
Past and Current Effectiveness of Cosmetic Safety Regulations and Future Direction, 63 
Food & Drug L. J. 257, 263 (2008). 
36 Id. (quoting 21 C.F.R. § 701.10; § 701.12 (2007)). 
37 Farren, supra note 6, at 384. 
38 Id. 
39 Id. 
40  Hartman, supra note 12, at 64.   11 
between  the  regulation  of  drugs  and  cosmetics  is  the  level  of  discretion  and 
voluntariness afforded to cosmetics that is not tolerated in the drug context.  
In the wake of the rapidly growing number of cosmeceuticals offered in the 
marketplace,  the  existing  classification  system  used  to  distinguish  cosmetics 
from  drugs  is  insufficient  to  address  these  products,  which  seemingly  fall 
somewhere between the two categories. As a result of the stale, bifurcated FDCA 
definitions, the current legal system is both inefficient and ineffective at regulating 
cosmeceuticals,  for  which  “often  no  more  than  a  fine  line  exists  between 
cosmetic  and  drug  classification.”
41  Given  the  vastly  divergent  regulatory 
requirements  placed  on  drugs  and  cosmetics,  a  cosmeceutical  producer  will 
clearly  try  to  stay  on  the  cosmetics  side  of  the  divide, t hereby  avoiding  the 
expensive  pre-approval  and  compliance  requirements  imposed  on  drugs.  And 
because categorization is based on intended use, the FDA will be limited in its 
ability to force an article under the stricter drug definition. Unless the FDA is able 
to  scare  the  manufacturer  into  toning  down  efficacy  claims  through  warning 
letters, the only other means by which it can properly regulate a cosmeceutical is 
if  the  agency  chooses  to  bring  a  suit  challenging  the  misclassification  of  the 
product as a cosmetic rather than as a drug.
42  
                                                        
41 Farren, supra note6, at 385. 
42 Bryan A. Liang and Kurt M. Hartman, Itʼs only skin deep: FDA Regulation of Skin Care 
Cosmetics Claims, 8 Cornell J.L. & Pub. Polʼy 249, 252 (1999).   12 
However this approach is costly, and does not always lead to consistent 
outcomes as demonstrated by the Wrinkle Remover Cases of the 1960s.
43 In 
three  very  similar,  closely  litigated  cases  involving  cosmetic  products  that  all 
contained solutions of bovine serum albumin in water, the FDA was successful in 
convincing only two of the three courts to categorize the respective product as a 
drug based on the manufacturerʼs claims, which suggested an intent to affect the 
structure  of  the  body  (e.g.  “a  face  lift  without  surgery”).
44  The  incongruous 
treatment  of  virtually  identical  products  demonstrates  the  inadequacy  of  the 
current  regulatory  process,  especially  in  the  face  of  an  increasing  number  of 
categorically  ambiguous  cosmeceuticals.  Protecting  consumers  in  this  limited, 
haphazard way is simply not good enough. Furthermore, due to limitations in 
FDA  resources  and  the  historically  weak  FDA  enforcement  of  the  regulations 
promulgated under the FDCA, “cosmetics companies have been free to make 
more bold and daring claims with each new advertisement and still avoid having 
its products classified as a drug.”
45 Hence if this binary framework continues to 
dictate  the  regulatory  treatment  of  cosmeceuticals,  these  manufacturers  are 
unfairly permitted to have their cake and eat it too. By selling products that “look, 
sound, feel--and cost--a lot like drugs or other FDA-approved therapies,”
46 but 
                                                        
43 See generally, Hutt, supra note 10, at 229-30; Liang and Hartman, supra note 42, at 
252-255.   
44  Greff, supra note 14, at 252 (summarizing the court holdings in: United States v. “Line 
Away,” 284 F. Supp. 107 (D. Del. 1968), aff'd, 415 F.2d 369 (3d Cir. 1969); 
United States v. “Sudden Change,” 288 F. Supp. 29 (E.D.N.Y. 1968), rev'd, 409 F.2d 
734 (2d Cir. 1969); United States v. “Magic Secret,” 331 F. Supp. 912 (D. Md. 1971)). 
45 Hartman, supra note 12, at 60. 
46 Kawalek supra note 3, at 54.   13 
are only subject to lenient cosmetics regulations, cosmeceutical makers are able 
to economically benefit, while consumers are unnecessarily exposed to potential 
physical  and  economic  harm.  The  heightened  stakes  associated  with 
inadvertently permitting cosmeceuticals to enter the market without “information 
as to safety precautions, adverse side-effects, or efficacy,”
47 emphasize the need 
for greater FDA oversight of these products so that they are properly monitored 
when they are introduced in the marketplace, instead of only after the fact. 
 
Part III: Modern Day Cosmeceuticals – Eyelash Enhancing Serums, Anti-
Aging Creams with Stem Cell Technology and DNA Repair Lotions 
   
To further demonstrate the extent to which existing regulations fail to satisfy the 
needs of the current cosmetic landscape, this section will analyze several of the 
new  popular  cosmeceuticals  that  are  already  available  on  the  market.  The 
products  discussed  highlight  the  regulatory  gap  in  the  present  system,  and 
exemplify why the FDA needs to impose a greater level of regulation specifically 
on cosmeceuticals.  
 
A. Eyelash Growth/Enhancing Products: Latisse vs. Competing Cosmeceuticals   
  For  centuries,  women  have  looked  for  ways  to  make  their  eyelashes 
appear  darker,  longer  and  fuller.  Products  like  mascara  and  false  adhesive 
lashes  (which  now  include  professional  lash  extensions)  have  traditionally 
satisfied this desire. However in the past few years, a new batch of products 
                                                        
47 Liang and Hartman, supra note 42, at 258.   14 
have  been  developed  and  marketed  that  claim  to  actually  stimulate  the 
lengthening and thickening of oneʼs own lashes. These eyelash growth serums 
arguably go beyond enhancing oneʼs appearance as they are said to promote 
actual lash growth.
48  Yet of the many products that are available for purchase,
49 
only one has been FDA-approved as a legitimate eyelash growth drug.  
In December of 2008, the FDA approved the drug Latisse (manufactured 
by the pharmaceutical giant Allergan), a prescription treatment that can be used 
to promote eyelash growth and make them “longer, thicker and darker.”
50  Latisse 
contains the active ingredient bimatoprost ophthalmic solution, a prostaglandin 
analogue, which is also used in Allerganʼs glaucoma drug Lumigan.
51 Though the 
formula of the two drugs is nearly identical, the application of the two differs as 
Latisse is used as a topical serum applied on the upper eyelid margin at the base 
of the eyelashes, whereas Lumigan is administered as an eyedrop.
52 In the fall of 
2009, less than a year after the productʼs launch, Allergan received a warning 
letter  from  the  FDA  stating  that  many  of  the  claims  included  on  the  Latisse 
website were misleading and failed to adequately reflect the risks associated with 
the product, in violation of the FDCA (21 U.S.C. 352(a) & 352(n)) and several 
FDA  implementing  regulations  (21  CFR  202.1(e)(3)(i);  (e)(5)  &  (e)(7)(viii)).
53 
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Some of the serious risks associated with this product that were not properly 
addressed included “effects on intraocular pressure, permanent iris pigmentation, 
semi-permanent  lid  pigmentation,  hair  growth  outside  the  treatment  area, 
intraocular inflammation, macular edema, contamination of Latisse or applicators, 
and potential adverse reactions with contact lenses.”
54 The FDA requested that 
Allergan “immediately cease the dissemination of violative promotional materials 
for  Latisse  …and  submit  a  written  response  …  explaining  [its]  plan  for 
discontinuing the use of such violative materials.”
55 
The FDAʼs treatment of Latisse demonstrates the high level of oversight 
and  consumer  protection  that  is  provided  for  drug  compounds.  Not  only  was 
Latisse subject to a comprehensive premarket approval process, but it has also 
been subject to ongoing FDA monitoring and surveillance. Moreover, when the 
FDA finally did approve Latisse for marketing, “they made a determination that 
the side effects or misuse or inappropriate use could cause harm, and thatʼs why 
they restricted it to a prescription drug…if it was completely safe to use without 
doctor supervision, they would have deemed it over-the-counter.”
56 It is thus quite 
startling  to  discover  that  there  are  a  number  of  similar  lash-growing cosmetic 
products  currently  available  on  the  market  that  have  not  been  subject  to  the 
same  regulatory  rigors  as  Latisse.  Two  competing  cosmetics  products  in 
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particular,  Athena  Cosmeticsʼ  Revitalash  and  Jan  Mariniʼs  Age  Intervention 
Eyelash Conditioner are especially interesting because they were both originally 
sold  with  formulas  containing  the  same  drug  ingredient  bimatoprost.  The  Jan 
Marini  product  was  launched  in  2005,
57  while  Revitalash  was  introduced  in 
2007.
58 Notably, both of these cosmeceuticals were offered for sale before the 
FDA had officially approved Latisse, and both went to market without any FDA-
sponsored testing given their positioning as cosmetics. Since cosmetics are not 
required  by  the  FDA  to  list  the  side  effects  associated  with  their  products 
(presumably because the majority of traditional cosmetics should not cause any), 
these  cosmeceuticals  were also  available  to  consumers  without  proper  safety 
warnings. When one recognizes the gravity of the potential risks that may stem 
from the misuse of a product containing a prescription ingredient like bimatoprost, 
it  is  quite  shocking  to  think  that  these  unregulated  products  were  so  easily 
allowed on the market.  
In November of 2007, the FDA finally confiscated over 12,000 applicator 
tubes of Jan Mariniʼs Age Intervention Eyelash Conditioner as “an unapproved 
and misbranded drug [given] Jan Marini Skin Research promoted the product to 
increase eyelash growth… and as an adulterated cosmetic [given] the productʼs 
[inclusion  of]  bimatoprost.”
59  The  FDA  claimed  it  feared  for  the  “safety  of  the 
                                                        
57 See Jan Marini, http://www.janmarini.com/us/viewPrd.asp?idproduct=50 (last visited 
April 1, 2011). 
58 Katharine Griffiths, The Innovator, COSMETIC SURGERY & AESTHETICS TODAY (Feb. 23, 
2011) http://www.cosmeticsurgerytoday.co.uk/features/view/10536/the-innovator/ 
59 FDA News Release, available at 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109028.htm    17 
consumers who purchased the product,”
60 however by the time the product was 
seized  by  the  FDA,  the  sale  and  production  of  this  particular  version  of  the 
product  was  already  banned  by  the  California  Department  of  Public  Healthʼs 
Food and Drug Branch.
61 In fact, Jan Marini had already reformulated its lash 
enhancer  product  so  that  it  was  based  on  non-prostaglandin  technology 
consisting of a proprietary blend of peptides.
62 That the FDA only took action 
after the fact demonstrates just how ineffective the current regulatory structure is 
in monitoring cosmeceuticals in an appropriate and timely fashion. Additionally, 
the  initially  disparate  treatment  of  Latisse  and  these  virtually  identical 
cosmeceutical products, further highlights the serious gap that exists in the FDA 
framework.  
Perhaps even more concerning is the fact that the FDA did not take similar 
action  against  any  other  eyelash-enhancing  cosmetic  product,  even  though 
several other brands contained similar prostaglandin ingredients.
63 Some reports 
claim that the FDAʼs action against Jan Mariniʼs product was enough to prompt 
the  makers  of  Revitalash  and  the  creators  of  Enormous  Lash  (yet  another 
eyelash enhancing serum) to voluntarily reformulate their products.
64 However 
based on several other consumer review sites, it is unclear whether Revitalash 
actually  reformulated  its  product  to  get  rid  of  all  forms  of  prostaglandin 
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analogues,  or  simply  replaced  its  use  of  bimatoprost  with  Trifluoromethyl 
Dechloro Ethylprostenolamide, a prostaglandin derivative that works in a similar 
fashion to stimulate lash growth.
65 Perhaps the fact that Allergan sued seven 
cosmetic companies including Athena Cosmeticʼs and the makers of Enormous 
Lash, for an alleged patent infringement based on their use of prostaglandins in 
their  cosmeceutical  products,
66  suggests  the  FDA  did  not  go  far  enough  to 
protect consumers from these under-regulated eyelash growth products. In any 
case, resting the safety of consumersʼ health on the conscience of manufacturing 
companies is a precarious position to take. Rather, a more effective and less 
risky approach would be for the FDA to subject all such products to a stricter and 
more uniform review.  
Furthermore,  even  if  several  cosmeceutical  manufacturers  removed  the 
potentially dangerous prostaglandin ingredients from their products subsequent 
to the FDAʼs seizure of Jan Mariniʼs product, these companies continue to sell 
products  they  ostensibly  claim  promote  eyelash  growth.  Although  some 
manufacturers  are  careful  to  state  that  their  products  are  only  intended  to 
“enhance the appearance of eyelashes, or deliver gorgeous, dense and lush-
looking eyelashes,”
67 oftentimes, they also include before and after pictures, user 
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testimonials and doctor-backed stamps of approval in their marketing materials, 
which insinuate how these products are really intended to work. Consequently, 
this may lead to rampant consumer confusion over which products are actually 
safe,  effective  and  properly  regulated.  The additional  fact  that  many  of  these 
cosmeceuticals  are  priced  similar  to  the  Latisse  drug  despite  unsubstantiated 
efficacy  claims,  at  a  minimum,  exposes  consumers  to  unnecessary  economic 
harm.  The  trouble  again  seems  to  stem  from  the  extremely  different  legal 
treatment that is afforded to products based on whether it is defined as a drug or 
cosmetic.  When  remarkably  similar  products  are  regulated  in  diametrically 
opposite manners, simply due to the promotional materials of the manufacturers, 
the  failures  of  the  existing  regulatory  regime  are  made  grossly  apparent.  All 
cosmeceuticals  need  to  be  given comparable  regulatory  treatment  if  the  FDA 
wants to efficiently and effectively deal with the problems that can arise from 
such products.  
 
B. The Latest Anti-Aging Craze: Stem Cells as the New Alpha-Hydroxy Acids 
  In  the  early  1990s,  products  containing  Alpha-Hydroxy  Acids  (AHAs) 
became ubiquitous on the mass market and they were heralded in as THE anti-
aging  solution.
68  When  topically  applied,  AHAs  exfoliate  the  top  layer  of  skin, 
thereby  exposing  the  “fresher-looking  skin  underneath…[providing  a]  milder 
cosmetic version of a chemical peel at home.”
69 Because AHA products were 
                                                        
68 Farren supra note 6, 389. 
69 Id.   20 
generally  categorized  as  cosmetics,  they  were  able  to  avoid  FDA  premarket 
clearance, and thus the negative side effects and health risks associated with 
high  concentrations  of  AHAs  were  not  fully  known  until  after  the  product  had 
already widely penetrated the market. The side effects, which included “severe 
redness,  swelling,  burning,  blistering,  bleeding,  rash,  itching  and  skin 
discoloration,”
70 made it obvious that AHAs were non-traditional cosmetics and 
“unlike anything else ever introduced onto the cosmetic market on such a wide 
scale.”
71 As the number of complaints grew, it became clear that AHAs did “exert 
an effect on the skin… affecting the structure and function of the body and that 
they  should  be  regulated  as  drugs.”
72  However,  because  the  treatment  of 
cosmeceuticals remained subject to the drug/cosmetic distinction, the FDA was 
limited in how it could properly address the AHAs problem. Ultimately, the FDA 
chose not to attempt a forced drug classification on these products but rather 
only recommended labeling guidance (specifically, the inclusion of a “sunburn 
alert”  warning)  for  cosmetics  containing  AHAs.
73  This  ultimately  unsatisfactory 
resolution  of  the  treatment  of  AHAs,  one  of  the  first  major  anti-aging 
cosmeceuticals,  has  left  the  door  open  for  the  continued  inadequate  legal 
treatment of anti-aging products.  
Given the rapid pace of science and technology development, it seems 
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that every few years, a new and even better anti-aging miracle cosmeceutical is 
introduced into the marketplace for consumers to try. Though these products may 
just  be  marketing  gimmicks  that  attempt  to  trick  the  gullible  into  buying  yet 
another expensive but ineffective skincare product, the problem is that in this new 
era of cosmetics with its constantly evolving technologies, we often do not know 
whether the product is safe, dangerous, or simply ineffective until after it has 
already been introduced. The latest craze in anti-aging appears to be skincare 
creams containing “stem cells,” which have become quite vogue in the past few 
years.
74  Stem-cell  technology  is  said  to  be  “revolutionizing  skin  care”  and 
manufacturers of stem cell creams are claiming that their emulsions are capable 
of “rejuvenat[ing] skin by awakening your bodyʼs own reservoir of undifferentiated 
stem cells.”
75 One stem cell cream company stated in a press release that its 
“recorded sales are skyrocketing as the word gets out of the product.”
76 
Like  their  AHAs  predecessors,  the  problem  with  these  new  stem  cell 
creams  is  that  they  are  able  to  reach  the  market  under  the  lax  cosmetics 
definition while the efficacy and science behind these products is not fully known. 
Even  the  exact  technology  used  in  these  creams  remains  ambiguous.  Some 
products  available  on  the  market  such  as  the  Bio  Therapie  cream  and  the 
PhytoCellTec line of creams offered by the Mibelle Biochemistry Company, use 
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plant stem cells that are said to help combat aging by positively impacting the 
vitality of human skin stem cells.
77 Several other products, such as Stem Cell 
Therapy  by  BioLogic  Solutions  and  Amatokin  Emulsion  utilize  “stem  cell 
technology,”  using  peptides  to  activate  the  deeper  layers  of  skin  that  contain 
adult  stem  cells  and  stimulate  them  to  produce  fresh  new  skin  cells.
78  Still, 
another group of international biotech firms including RNL Bio and Prostemics 
have created cosmetics that contain stem cell culture fluid – “liquid that has been 
used to culture stem cells but does not actually contain any human tissue.”
79 
However, the fact that no stem cell cream currently uses human stem cells does 
not necessarily mean they will never use them in the future. The possibility that 
some  manufacturers  will  explore  this  option  is  not  entirely  out  of  the  picture 
(absent stricter regulation), especially if companies “attempt a race to the top…to 
achieve a more drastic effect,”
80 as was seen with the AHAs products.  
Yet even when we limited the inquiry to the existing products available on 
the  market  today,  it  is  not  entirely  clear  that  consumers  are  not  at  risk.  For 
example, the stem cell culture fluid used in some products is extracted from fat 
tissues  sourced  from  hospitals;  because  the  fat  tissues  come  from  various 
liposuction  surgeries,  there  may  be  serious  risks  of  viral  and  bacterial 
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contamination in the materials.
81 Concerned with the potential health risks that 
could  be  posed  by  this  unfamiliar  ingredient,  the  Korean  Food  and  Drug 
Administration  temporarily  banned  the  use  of  culture  fluids  in  cosmetics.
82 
Though  they  are  no  longer  on  the  banned  ingredients  list,  the  KFDA  has 
continued  to  study  the  best  way  to  regulate  the  newly  developed  stem-cell 
creams.
83 The American FDA should similarly explore more stringent means of 
regulating these new cosmeceuticals. Although the FDA has taken some action, 
and sent a warning letter to one stem cell cream manufacturer in early March 
2011, claiming that the promotions contained on JabaLabsʼs websites caused 
their  products  to  be  drugs,
84  the  company  simply  had  to  correct  its  labeling 
violations by toning down the claims made for its product, to avoid enforcement 
action.
85 The FDA did no more to inquire into the productsʼ safety or efficacy and 
the  manufacturer  is  still  able  to  continue  selling  its  creams  to  consumers. 
Arguably this is not enough to protect consumers from potential risks. 
Even if the manufacturers of stem cell creams are only engaging in mere 
puffery, in the face of such new and untested science, the FDA cannot permit 
these products to escape close scrutiny by simply hiding under the cosmetics-
definition. Without some form of premarket screening or ongoing FDA oversight, 
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consumers will likely discover the potential range of adverse side effects, both 
short-term and long-term, after the fact. And as to cosmetics, the FDA currently 
has no authority to directly recall these products, even if they are later found to 
be harmful.
86 The aggressive marketing used for these products like “the first 
anti-aging cream that will help restore the potential of skin stem cells and bring 
back the skin of youth”
87 despite uncertainties in effectiveness, coupled with the 
potential health dangers that may exist in this unfamiliar technology, present the 
extremely  detrimental  combination  of  imposing  serious  harm  on  consumersʼ 
health  and  finances.  Products  like  these  new  stem  cell  creams  again 
demonstrate the need for greater FDA regulation over emerging cosmeceuticals, 
and call for reform to ensure harms are detected before harms are borne by 
consumers. 
 
Part  IV:  Proposals  for  Possible  Reform  and  the  Case  for  a  New 
Cosmeceutical Subcategory 
 
The  argument  in  support  of  modifying  existing  law  to  impose  stricter 
regulations on cosmeceuticals and the broader cosmetic industry is neither novel 
nor radical. Over the years, there have been many attempts to amend the FDCA 
and  yet  they  have  all  been  ultimately  unsuccessful.  However,  in  light  of  the 
growing  market  for  cosmeceuticals,  the  ever-changing  technologies  used  by 
cosmetics manufacturers, and the constantly developing pool of ingredients, the 
time is upon us to seriously evaluate how the FDA can better regulate modern 
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day  cosmetics.  Proposals  that  have  been  suggested  in  the  past  include 
“adjusting the existing cosmetic and drug regulatory categories, adding a third 
category, or requiring premarket testing.”
88 All have their own merits as well as 
their fair share of noteworthy critiques. However, what remains clear is that the 
current framework needs fixing.  
Threatening to define every cosmetic product that offers drug-like effects, 
as  a  drug, i s  neither  efficient  nor  ideal  for  providing  consumers  with  the 
appropriate level of protection from physical and economic harm. The number of 
cosmeceutical products available on the market is enormous, and new products 
are  continuously  being  launched.  Without  any  forced  requirements  to  register 
with the FDA, it is simply too difficult to fix the cosmeceutical problem with an 
after the fact type approach. Moreover simply requiring all cosmeceuticals to be 
regulated as de facto drugs by constructively inferring intended use based on the 
presence  of  an  active  ingredient  is  equally  inefficient.  Though  this  approach 
would be administratively easier from a classification standpoint, it would also 
result  in  “inordinately  high  resource  expenditures,  because  proof  of  efficacy 
would be required even for those products about which relatively benign claims 
were made.”
89  
Instead, given the term cosmeceutical is already widely recognized by the 
industry,  consumers,  dermatologists,  academics  and  even  the  regulators,  the 
FDA  should  formally  acknowledge  cosmeceuticals  as  a  valid  legal  term.  In 
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providing  legal  recognition  for  cosmeceuticals  as  a  distinct  group of  cosmetic 
products with drug-like qualities, the FDA can take its first step towards a better 
regulatory approach in handling these currently difficult-to-categorize products. 
Although introducing a new statutory definition is always difficult and contentious, 
the fact that this term already has a generally recognized colloquial meaning is 
helpful.  Working  off  a  definition  proffered  by  Laura  Heymann,  cosmeceuticals 
could be defined as “those products containing an active ingredient for which 
cosmetic claims are made.”
90  
Given  the  existent  infrastructure  and  resource  limitations,  it  may  be 
favorable to introduce cosmeceuticals as a subgroup to either the cosmetics or 
drugs category. However, given the relatively lenient regulation of cosmetics and 
the overly restrictive regulation of drugs, the arguably better approach would be 
to create an altogether separate category for cosmeceuticals, which would be 
subject to its own set of regulations and requirements. In doing so, the FDA may 
want  to  use  the  Japanese  model  as  a  potential  starting  point.  In  Japan,  a 
separate  set  of  regulations  exists  to  cover  “cosmetic  products  with 
pharmacological action called quasidrugs, which are ranked between cosmetics 
and  drugs.”
91  The  manufacturers  of  these  quasidrugs  are  “required  to  obtain 
government approval before marketing, [which] is contingent upon a judgment by 
the Ministry of Health and Welfare regarding its adequacy as a quasidrug in view 
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of  its  effectiveness,  safety,  etc.”
92  Furthermore,  the  level  of  data  and 
documentation  that  is  required  is  directly  contingent  on  the  type  of  quasidrug 
being offered for approval; the indications and effects of the proposed product as 
well as the newness of the quasidrug all have a bearing on what is necessary for 
the  review  process.
93  Other  Asian  jurisdictions  that  have  adopted  a  similar 
approach include Thailand, which distinctly regulates “controlled cosmetics” and 
Hong Kong, which has a category for “cosmetic-type drugs.”
94  
Regardless of whether or not the FDA chooses to apply a similar approach 
as  Japan  in  adopting  some  sort  of  sliding  premarket  approval  process,  there 
should  at  least  be  some  base  level  of  safety  screening  imposed  on 
cosmeceuticals before they are allowed to go to market. Requiring companies to 
submit safety reports to a federal agency will help ensure uniformity across the 
market  and  make  certain  consumers  are  not  exposed  to  dangerous 
cosmeceuticals. These reports could outline the types of testing that have been 
conducted by the companies, subject of course to some obligatory industry-level 
minimum, though these reports could be less extensive than the types of reports 
currently required for new drugs. In addition, like drug companies, manufacturers 
of cosmeceuticals should be required to participate in a mandatory registration 
process  for  all  products  and  manufacturing  establishments.  Since  there  are 
heightened risks and potentially delayed effects that may stem from the use of 
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cosmeceuticals,  having  an  accurate  and  up-to-date  database  of  products  and 
companies will aid the FDA in properly regulating cosmeceuticals on an on-going 
basis.  
Finally,  with  regards  to  the  aggressive  marketing  and  shaky  efficacy 
claims  often  made  by  cosmeceutical  makers,  consumers  may  also  need 
additional  economic  protection  as  many  of  these  cosmeceuticals  cost  a  great 
deal more than traditional cosmetics (without the guarantee of effectiveness). If 
cosmeceuticals are regulated as a separate category and subject to premarket 
safety requirements, one option may be to require certain efficacy requirements 
be satisfied as well. However, because most of these products are still primarily 
focused on providing cosmetic (though increasing scientific) benefits rather than 
offering actual drug treatments, efficacy concerns will likely be less pressing for 
the  FDA.  Instead,  one  option  the  FDA  may consider  exploring  is  establishing 
some sort of uniform claims list to address commonly made cosmetic product 
claims.  The  FDA  could  set  its  own  minimum  standard  of  what  constitutes  a 
“dermatologist-tested”  product  or  “hypoallergenic”  cosmetic,  and  then  require 
manufacturers  to  conform  to  the  FDA  level  of  expectation  before  they  are 
permitted to make such claims in their product marketing. While this solution may 
present some budgetary concerns of its own in order to be effectively enforced, 
this  option  is  likely  less  expensive  than  requiring  the  FDA  to  regulate  and 
approve efficacy levels in cosmeceuticals. In turn, if manufacturers are confined 
in  their  ability  to  make  confusing,  unsubstantiated  marketing  claims  in  the   29 
absence of meeting FDA thresholds, consumers will be afforded some additional 
protection from economic harm. Alternatively, the FDA could also come up with 
an enumerated list of tolerated claims for each type of cosmeceutical (e.g. anti-
aging creams, eyelash enhancers etc.). Presumably, the tolerated claims would 
be more reserved than companies would ideally like. However, if a manufacturer 
wanted to assert greater claims in order to receive higher prices for its products, 
they  would  still  have  the  option  of  marketing  their  product  as  a  drug.  But  by 
limiting the realm of outlandish claims that a producer could make cosmeceutical 
products, the FDA may provide consumers with some much needed additional 
economic protection.    
 
Part V: Conclusion 
  The  modern  cosmetics  industry  is  rapidly  changing.  As  science  and 
technology  become  increasingly  sophisticated,  our  society  is  witnessing  a 
change in the types of cosmetic products that are offered on the marketplace 
today. Over the past few years, cosmeceuticals have grown significantly and they 
now  represent  the  fastest  growing  segment  of  the  personal  care  products 
industry.  Thus  as  more  and  more  cosmetics  become  increasingly  drug-like  in 
their  composition  and  offerings,  it  is  crucial  for  the  law  to  finally  catch  up. 
Adhering to the old drug/cosmetic definitional distinction is no longer adequate 
when so many products blur the line. The FDA should no longer tolerate wildly 
divergent regulatory treatment of two similar products, which may occur under   30 
the  current  system,  simply  based  on  the  manufacturersʼ  intended  use  for  the 
products.  Instead, in order to properly regulate this new generation of products, 
the  FDCA  should  be  amended  to  reflect  a  new  category  of  regulations  and 
requirements, specifically tailored to cosmeceutical products. By increasing the 
safety requirements imposed on cosmeceuticals and simultaneously limiting the 
ability of manufacturers to make overly inflated efficacy claims, consumers could 
be significantly better protected from physical and economic harms. The time is 
upon us to finally amend the FDCA and bring it in line with the modern day needs 
in the areas of cosmetics, drugs and cosmeceuticals.  
 
 
 
 
 
 
 
 